Bank of Montreal Can Has $1.44 Million Holdings in Intercept Pharmaceuticals Inc (ICPT)

Bank of Montreal Can grew its position in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 15.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,240 shares of the biopharmaceutical company’s stock after buying an additional 1,877 shares during the quarter. Bank of Montreal Can’s holdings in Intercept Pharmaceuticals were worth $1,435,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. FMR LLC increased its holdings in shares of Intercept Pharmaceuticals by 17.5% in the 2nd quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock valued at $372,336,000 after purchasing an additional 661,542 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Intercept Pharmaceuticals by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,952,931 shares of the biopharmaceutical company’s stock valued at $246,772,000 after purchasing an additional 54,038 shares in the last quarter. Vanguard Group Inc increased its holdings in shares of Intercept Pharmaceuticals by 2.8% in the 3rd quarter. Vanguard Group Inc now owns 1,952,931 shares of the biopharmaceutical company’s stock valued at $246,772,000 after purchasing an additional 54,038 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of Intercept Pharmaceuticals by 29.9% in the 3rd quarter. First Trust Advisors LP now owns 1,092,319 shares of the biopharmaceutical company’s stock valued at $138,025,000 after purchasing an additional 251,735 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of Intercept Pharmaceuticals by 24.9% in the 3rd quarter. Deutsche Bank AG now owns 438,720 shares of the biopharmaceutical company’s stock valued at $55,435,000 after purchasing an additional 87,473 shares in the last quarter. Institutional investors own 63.48% of the company’s stock.

A number of equities analysts have recently issued reports on ICPT shares. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $113.00 price target for the company in a report on Tuesday, November 13th. Wedbush set a $220.00 price target on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 6th. BidaskClub downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 1st. UBS Group started coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, January 23rd. They issued a “buy” rating and a $130.00 price target for the company. Finally, B. Riley started coverage on shares of Intercept Pharmaceuticals in a report on Tuesday, December 11th. They issued a “buy” rating and a $155.00 price target for the company. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $159.06.

In related news, EVP Christian Weyer sold 1,343 shares of the stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $113.78, for a total value of $152,806.54. Following the sale, the executive vice president now directly owns 17,162 shares of the company’s stock, valued at approximately $1,952,692.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David Shapiro sold 474 shares of the stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $97.48, for a total transaction of $46,205.52. Following the completion of the sale, the insider now directly owns 37,243 shares in the company, valued at $3,630,447.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 812,130 shares of company stock worth $85,159,685. 4.90% of the stock is owned by corporate insiders.

Shares of NASDAQ ICPT opened at $110.35 on Thursday. The stock has a market capitalization of $3.29 billion, a P/E ratio of -7.67 and a beta of 1.88. Intercept Pharmaceuticals Inc has a 52 week low of $51.76 and a 52 week high of $133.74. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98.

TRADEMARK VIOLATION NOTICE: This news story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2019/02/14/bank-of-montreal-can-has-1-44-million-holdings-in-intercept-pharmaceuticals-inc-icpt.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

See Also: What is the Coverage Ratio?

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply